What did @spellpsqj9z actually say?
Honestly? Not much. The transcript for this 371,900-view video is just a repeated phrase about making a new video, with no actual commentary delivered. The caption does the heavy lifting here: "Celebrity Ozempic Face Before and After" with a weightloss hashtag. Whatever appeared visually, the spoken content is essentially empty. That means we're fact-checking a concept the caption invokes, not a real argument the creator made out loud.
"Ozempic face" is a term that's been circulating since 2023, popularized in outlets like the New York Times and on platforms like this one. It refers to the gaunt, hollowed, or aged facial appearance some people report after significant GLP-1-driven weight loss. The caption frames this as a celebrity phenomenon. That framing alone carries implicit claims worth examining.
Does the science back this up?
The core idea that rapid or significant weight loss can change facial appearance is well-supported. The term "Ozempic face" as a clinical entity, though, is almost entirely media-manufactured. There is no published clinical trial specifically studying semaglutide-induced facial changes as a distinct outcome.
What we do know: fat redistributes during weight loss, and the face is not immune. A 2022 study by Pessa and Rohrich in Plastic and Reconstructive Surgery documented that facial fat compartments deflate with aging and weight loss, contributing to volume loss in the cheeks, temples, and periorbital areas. This process is not specific to GLP-1 drugs. Any intervention that produces meaningful weight loss, whether dietary, surgical, or pharmacological, can produce similar effects.
The STEP trial series (Wilding et al., 2021, New England Journal of Medicine) showed semaglutide producing average weight loss of roughly 15% of body weight over 68 weeks. That degree of loss absolutely can affect facial volume. But the drug itself is not directly causing facial aging. The weight loss is.
What did they get wrong (or right)?
Attributing facial changes specifically and exclusively to Ozempic is where this narrative gets sloppy. The creator's caption implies that GLP-1 drugs do something unique to the face. That's misleading by framing. A person who lost the same amount of weight through caloric restriction alone would likely show similar changes. Dermatologists including Dr. Shereene Idriss have noted publicly that the rate of weight loss may matter, with faster loss leaving less time for skin elasticity to adapt, but that's still about weight loss speed, not the drug class itself.
To give partial credit where it's due: the general observation that dramatic weight loss can age the face is not wrong. It's a real phenomenon patients and clinicians should discuss before starting GLP-1 therapy. The problem is that the "celebrity before and after" format treats this as gossip rather than a clinical conversation. Patients deserve better than speculation about public figures' prescriptions.
What should you actually know?
If you're considering a GLP-1 medication, facial volume change is a legitimate topic to discuss with your provider, not because the drug is doing something sinister to your face, but because significant weight loss has cosmetic consequences that aren't always discussed upfront.
A few things worth knowing:
- Facial fat loss during weight loss is well-documented and is not specific to any drug class.
- The rate of weight loss may influence skin laxity outcomes, though this needs more direct research in GLP-1 populations.
- Dermal fillers and skin-tightening procedures are options some patients explore, though these carry their own risks and costs.
- There is no clinical evidence that semaglutide or tirzepatide accelerates facial aging beyond what equivalent weight loss by other means would produce.
- The STEP 1 trial (Wilding et al., 2021) showed that most participants regained significant weight after stopping semaglutide, which could also affect facial appearance in reverse.
The "Ozempic face" framing is catchy and drives clicks. It's not a diagnosis. Patients should approach this topic with their prescribing clinician, not a TikTok before-and-after carousel.